A scaffold vaccine to promote tumor antigen cross-presentation via sustained toll-like receptor-2 (TLR2) activation

A scaffold vaccine to promote tumor antigen cross-presentation via sustained toll-like receptor-2 (TLR2) activation

Cancer vaccination holds great promise for cancer treatment, but its effectiveness is hindered by suboptimal activation of CD8+ cytotoxic T lymphocytes, which are potent effectors to mediate anti-tumor immune responses. A possible solution is to switch antigen-presenting cells to present tumor antig...

Full description

Bibliographic Details
Main Authors: Daping Xie, Congwei Han, Chonghao Chen, Zhencheng Liao, Senio Campos de Souza, Yiming Niu, João F. Mano, Lei Dong, Chunming Wang
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2024-07-01
Series:Bioactive Materials
Subjects:
Scaffold vaccine
TLR2 agonist
Polysaccharide
Reactive oxygen species
Cross-presentation
Online Access:http://www.sciencedirect.com/science/article/pii/S2452199X24001269

Internet

http://www.sciencedirect.com/science/article/pii/S2452199X24001269

Similar Items